Table 1.
Records included in the systematic review
| Study type/data source | Study design | Investigated drugs | Investigated GLP1RA – dose | Investigated oral drug – dose | Population | Number, gender and age of subjects | |
|---|---|---|---|---|---|---|---|
| Kothare PA 2005 | PK study | Open-label, fixed-sequence | Exenatide – steady state, digoxin – steady state | Exenatide 10 mcg BID | Digoxin 0.25 mg | HS | 23 pts, M, 21–42 y |
| Blase E 2005 | PK study | RCT, single-blind, crossover | Exenatide – steady state, acetaminophen – single dose | Exenatide 10 mcg BID | Acetaminophen 1000 mg | HS | 40 pts, M+F, 18–65 y |
| Soon D 2006 | PK study | Open label, fixed-sequence | Exenatide – steady state, Warfarin – single dose | Exenatide 10 mcg BID | Warfarin 25 mg | HS | 16 pts, M, 22–50 y |
| Kothare PA 2007 | PK study | Open-label, fixed-sequence, | Exenatide – steady state, lovastatin – single dose | Exenatide 10 mcg BID | Lovastatin 40 mg | HS | 22 pts, M+F, 18–66 y |
| Linnebjerg H 2009 | PK study | RCT, double-blind, crossover | Exenatide – 2 doses, lisinopril – steady state | Exenatide 10 mcg BID | Lisinopril 5–20 mg qd | HS | 22 pts, M+F, mean age 60 ± 6.2 y |
| Kothare PA 2012 | PK study | Open-label, randomized, 3-period, crossover | Exenatide – steady state, COC – steady state | Exenatide 10 mcg BID | COC: EE 30 mcg, LV 150 mcg | HS pre-menopause | 38 pts, F, 18–45 y |
| Fujita Y 2013 | Case report | Exenatide | Hydrocortisone | ||||
| Liu YH 2010 | Conference abstract | Open-label, randomized, crossover | Lixisenatide – steady state, warfarin – single dose | Lixisenatide 20 mcg | Warfarin 25 mg | HS | 16 pts, M, age – ND |
| Dahmen R 2011 | Conference abstract | Open-label, randomized, crossover | Lixisenatide and ramipril – steady state | Lixisenatide 20 mcg | Ramipril 5 mg | HS | 30 pts, M+F, age – ND |
| Kapitza C 2011 | PK study | RCT, double-blind, 2-period crossover | Liraglutide – steady state, acetaminophen – single dose | Liraglutide 1.8 mg | Acetaminophen 1000 mg | DM2 | 18 pts, M+F, 48–70 y |
| Jacobsen LV 2011 | PK study | RCT, double-blind, 2-period crossover | Liraglutide – steady state, COC – single dose | Liraglutide 1.8 mg | COC: EE 30 mcg, LV 150 mcg | HS post–menopause | 21 pts, F, 51–71 y |
| Malm–Erjefält M 2015 | PK study | RCT, double-blind, 2-period crossover | Liraglutide – steady state, Atorvastatin, lisinopril and digoxin – single dose | Liraglutide 1.8 mg | Atorvastatin 40 mg, lisinopril 20 mg, digoxin 1 mg, | HS |
M+F, 18–55 y. Atorvastatin, lisinopril: 42 pts. Digoxin: 28 pts |
| Pinelli NR 2013 | PK study | Open-label, fixed-sequence | Liraglutide, tacrolimus – steady state | Liraglutide 1.8 mg | Tacrolimus various doses for goal trough concentration 5–15 ng/mL | Kidney transplant recipients, non-diabetic | 5 pts, M+F, 55.4 ± 8.2 y |
| Nagai Y 2019 | Case series | Liraglutide, exenatide – steady state, dexamethasone – single dose | Liraglutide 0.3–0.9 mg or exenatide 10–20 mcg BID | Dexamethasone 0.5 mg | DM2 | 7 pts | |
| Bush M 2012 | PK study | Open-label, sequential | Albiglutide – steady state, Digoxin, warfarin – single dose, COC– steady state | Albiglutide 50 mg | Digoxin 0.5 mg, warfarin 25 mg, and COC: EE 35 mcg, NE 500 mcg | HS pre-menopause |
Digoxin: 30 pts, M+F, 18–55 y Warfarin: 16 pts, M, 18–55 y COC: 23 pts, F, 18–40 y |
|
Young MA 2014 |
Review | Review – data extracted on specific DDI | Albiglutide – steady state, Simvastatin – single dose | Albiglutide 50 mg | Simvastatin 80 mg | HS | ND |
|
de la Peña A 2017 |
PK study | Digoxin, atorvastatin: fixed sequence Warfarin: randomized, crossover. COC: two treatment periods | Dulaglutide – single dose, warfarin/ atorvastatin – single dose, digoxin / COC – steady state | Dulaglutide 1.5 mg | Digoxin 0.25 mg, warfarin 10 mg, atorvastatin 40 mg and COC: EE 35 mcg and NG 250 mcg | HS pre-menopause |
Digoxin, warfarin: 16 pts, M+F, 18–65 y. Atorvastatin: 24 pts, M+F, 18–65 y. COC: 14 pts, F, 18–45 y |
| Tham LS 2018 | Conference abstract | Population– exposure–response and physiologic–based pharmacokinetics modeling | Dulaglutide – single dose | Dulaglutide 4.5 mg | Digoxin, warfarin, acetaminophen, lisinopril – doses not specified | DM2 and HS | Computerized modeling, no subjects enrolled |
| Kapitza C 2015 | PK study | Open-label, one-sequence, crossover | Semaglutide – steady state, COC – steady state | Semaglutide 1 mg | COC: EE 30 mcg, LV 150 mcg | HS post-menopause | 43 pts, F, mean age 62.2 ± 6 y |
| Hausner H 2017 | PK study | Open label, one-sequence, crossover | Semaglutide – steady state, warfarin / atorvastatin / digoxin – single dose | Semaglutide 1 mg | Warfarin 25 mg, atorvastatin 40 mg or digoxin 0.5 mg | HS |
M+F, 18–55 y. Warfarin: 23 pts. Atorvastatin, digoxin: 31 pts |
| Langeskov EK 2022 | PK study | Acetaminophen: open label, randomized, cross-over Atorvastatin: open-label, one-sequence, crossover | Semaglutide – steady state, Acetaminophen / atorvastatin – single dose | Semaglutide 1 mg | Acetaminophen 1500 mg, atorvastatin 40 mg |
Acetaminophen: HS obese (average BMI 33.2 kg/m2). Atorvastatin: HS |
M+F Acetaminophen: 29 pts, M+F, 21–65 y. Atorvastatin: 31 pts, M+F, 25–55 y |
| Meier JJ 2005 | PD study | Open-label, single-blinded, randomized, crossover | IV GLP 1, erythromycin – steady state? Metoclopramide, domperidone, cisapride – single dose | Intravenous GLP1 0.8 pmol* kg–1*min–1 for 270 min | Oral metoclopramide 10 mg, domperidone 10 mg, cisapride 10 mg, or IV erythromycin 200 mg/100 mL for 15 min | HS | 9 pts, M, mean age 25 ± 4 y |
BID twice daily, COC combined oral contraceptives, DM2 diabetes mellitus type 2, EE ethinylestradiol, F females, GLP1RA glucagon-like peptide 1 receptor agonists, HS healthy subjects, IV intravenous, LV levonorgestrel, M males, NE norethindrone, NG norelgestromin, PD pharmacodynamic, PK pharmacokinetic, RCT randomized controlled trial